GSK oncology return. STAT reported on October 26 that GSK used its ESMO presence, built around its antibody drug conjugates and Jemperli, to argue its return to cancer drug development is starting to pay off. It is a positioning claim rather than a new data set, carried here because GSK’s oncology rebuild is a standing competitive question for the ADC field. Source: STAT, October 26, 2026.
Treasury proposes biotechnology screening. The Treasury Department proposed rules that would add biotechnology to the technologies subject to outbound investment screening under the COINS Act framework, requiring United States investors to notify the government of certain China transactions and barring others, BioPharma Dive reported on October 26. Reporting by Reuters and Fierce Biotech cited in the same roundup indicates cross border drug licensing deals may not be meaningfully affected. Treasury is seeking public comment before finalizing. Source: BioPharma Dive, October 26, 2026, reporting the Treasury proposal of October 22, 2026.
Roche and most favoured nation pricing. Endpoints News reported on October 26 that Roche is changing launch plans in Europe as United States most favoured nation drug pricing pressure complicates the sequencing of European launches, since a low European price can now set a reference for the United States price. No single launch decision was announced. Source: Endpoints News, October 26, 2026.
House lawmaker probes PBM audits. A House lawmaker is probing pharmacy benefit managers over what independent pharmacies describe as punitive audits, STAT reported on October 26. It is an oversight step, not legislation, in the long running PBM reform debate. Source: STAT, October 26, 2026.
Employers accuse UnitedHealth of overpaying claims. Employers filed claims accusing UnitedHealth of overpaying medical claims in ways that increased their costs, Endpoints News reported on October 26. The company has not been found liable in the reporting read, and the item is carried as litigation news only. Source: Endpoints News, October 26, 2026.
HHS relaxes health record software rules. The Department of Health and Human Services moved to relax security and transparency requirements for hospital health record software in its HTI-5 rulemaking, STAT reported on October 26. Hospital and privacy groups are expected to contest the balance struck. Source: STAT, October 26, 2026.
UK clopidogrel recall. The UK regulator issued a Class 2 medicines recall on October 26 for Xeal Pharma clopidogrel oral liquids, all strengths, reference EL(26)A/43, through the official drug and device alerts channel. Pharmacies and wholesalers are the action audience. Source: UK government drug and device alerts, October 26, 2026.
Pennsylvania gene therapy company. Communities in Pennsylvania Dutch country, tired of waiting for biopharma to serve rare diseases concentrated in Amish and Mennonite populations, are building a drug company of their own, STAT reported on October 27. It is an organizational story with no financing figure in the reporting read. Source: STAT, October 27, 2026.
Imunon filings noted, no story. Imunon filed a Form S-1 registration statement and a Form 8-K (Item 8.01) on October 27 (accessions 0001493152-26-048630 and 0001493152-26-048625). The pool carried no terms or exhibit text for either filing, the EDGAR documents returned access errors in this run, and no material development could be verified, so neither filing is written as a story.